NASDAQ:VIRX
Viracta Therapeutics, Inc. Stock News
$0.81
-0.0298 (-3.55%)
At Close: May 03, 2024
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 06'th Feb 2024
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers
Viracta Therapeutics to Present at Upcoming Investor Conferences
04:15pm, Tuesday, 07'th Nov 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
04:15pm, Wednesday, 31'st May 2023
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pati
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04:05pm, Thursday, 11'th May 2023
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pati
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
04:30pm, Wednesday, 19'th Apr 2023
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pa
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
04:05pm, Wednesday, 08'th Mar 2023
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pa
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
04:05pm, Tuesday, 07'th Feb 2023
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pat
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
02:18pm, Thursday, 08'th Sep 2022
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
09:19am, Monday, 11'th Jul 2022
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.
4 Small Stocks to Bet on in an Upbeat Drugs Industry
10:54am, Wednesday, 06'th Jul 2022
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
04:15pm, Wednesday, 01'st Jun 2022
SAN DIEGO , June 1, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is sc
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
10:13am, Thursday, 07'th Apr 2022
SAN DIEGO , April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is
Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
04:30pm, Wednesday, 09'th Mar 2022
SAN DIEGO, March 9, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is s
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
12:13pm, Monday, 13'th Dec 2021
Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society o